Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA22007 (Ciclosporin 0.1%) in Moderate to Severe Dry Eye Syndrome
NCT00814515Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2007
- Primary completion
- Sep 2009
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine in dry eye syndrome (DED), sponsored by Santen Pharmaceutical. Started Sep 2007; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT00814515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814515.